Newark, CAFounded 20152+ employeesPrivate
Seed· last: seed (Mar 2016)· 1 rounds
Backed by(7 investors)
Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.
